In a recent retrospective study, patients with KRAS G12V- or G12A-positive advanced NSCLC who received first-line platinum-based chemotherapy with taxane had longer PFS than those who received platinum-based chemotherapy with pemetrexed or gemcitabine. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.